Breast augmentation is considered safe, but rare cases of breast implant-associated squamous cell carcinoma (BIA-SCC) have been reported. This study aimed to systematically review published cases of BIA-SCC, providing valuable clinical data. The review included 14 articles and 18 cases of BIA-SCC. An increasing trend in reported BIA-SCC cases was observed, with four cases in the 1990s and 14 cases since 2010. The mean age of affected patients was 56 years, and symptoms typically appeared around 21 years after breast augmentation. Silicone implants used in cosmetic procedures were most commonly associated with BIA-SCC. Implant removal was necessary in all cases, and some patients required a mastectomy. Treatment approaches varied, with the selective use of chemotherapy and/or radiotherapy. The estimated 6-month mortality rate was 11.1%, while the 12-month mortality rate was 23.8%. The estimated 6-month mortality rate should be cautiously interpreted due to the limited sample size. It appears lower than the rate reported by the American Society of Plastic Surgeons, without clear reasons for this discrepancy. This study highlights the importance of enhanced monitoring and information sharing to improve detection and management of BIA-SCC. Healthcare providers should maintain vigilance during the long-term follow-up of breast augmentation patients.
乳房增大术通常被认为是安全的，但已有罕见病例报告显示其可能与乳房假体相关鳞状细胞癌（BIA-SCC）有关。本研究旨在系统回顾已发表的BIA-SCC病例，提供有价值的临床数据。该综述共纳入14篇文献，涉及18例BIA-SCC病例。观察到报告的BIA-SCC病例呈上升趋势，其中1990年代有4例，2010年以来有14例。受影响患者的平均年龄为56岁，症状通常在乳房增大术后约21年出现。美容手术中使用的硅胶假体最常与BIA-SCC相关。所有病例均需移除假体，部分患者还需进行乳房切除术。治疗方法各异，选择性使用化疗和/或放疗。估计的6个月死亡率为11.1%，而12个月死亡率为23.8%。由于样本量有限，估计的6个月死亡率应谨慎解读。该死亡率似乎低于美国整形外科医师协会报告的数据，但差异原因尚不明确。本研究强调了加强监测和信息共享对于提高BIA-SCC检测和管理的重要性。医疗保健提供者应在乳房增大术患者的长期随访中保持警惕。
A Systematic Review of Breast Implant-Associated Squamous Cell Carcinoma
肿瘤(癌症)患者之家